Insmed Inc(INSM) Finding the best opportunities to buy and sell stocks daily.

Sector:

Healthcare

Description:

Insmed Incorporated, a biopharmaceutical company, focuses on the development and commercialization of therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients in the United States. It also develops INS1007, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug for the treatment of rare pulmonary disorders, including pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.

Current Price

$32.58

RSI

46.181

Beta:

2.309431

February 25, 2021
365M
-68.3M

-11.585 %
1.715 %
-93.002 %
-19.494 %

$134,849,000
$108,762,000
$-17,846,000
$-5,925,000
$-3,498,000
$0
23.985 %
116.408 %
-66.799 %
-40.962 %
0.000 %

$-292,698,000
$-253,537,000
$-324,099,000
$-192,921,000
$-176,175,000
$-120,154,000
-13.379 %
27.831 %
-40.475 %
-8.680 %
-31.798 %

News

Press Releases

Notable Dates

All stock recommendations and comments are all opinions. Investors should be cautious about any and all stock recommendations and should consider the source of any advice on stock selection. Various factors, including personal ownership, may influence or factor into a stock analysis or opinion. All investors are advised to conduct their own independent research into individual stocks before making a purchase decision. In addition, investors are advised that past stock performance is not indicative of future price action.